Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 1, 2015, Pages 110-118

  Baddeley, Thomas C ^a   McCaffrey, Jennifer ^b   Storey, John M D ^a   Cheung, John K S ^a   Melis, Valeria ^a   Horsley, David ^a   Harrington, Charles R ^a   Wischik, Claude M ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Salamandra LLC   (United States)

^c TAURX THERAPEUTICS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCOMETHYLTHIONINIUM; METHYLENE BLUE; PLACEBO; PROTEIN INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTICENTER STUDY (TOPIC); NONHUMAN; OXIDATION REDUCTION REACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ABSORPTION; ADOLESCENT; ANIMAL; BRAIN; CHEMISTRY; CLINICAL TRIAL; EATING; ERYTHROCYTE; METABOLISM; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PROTEIN AGGREGATION, PATHOLOGICAL; RANDOMIZED CONTROLLED TRIAL; TRANSPORT AT THE CELLULAR LEVEL; YOUNG ADULT;

ABSORPTION, PHYSICOCHEMICAL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ERYTHROCYTES; FEMALE; HUMANS; MALE; METHYLENE BLUE; MICE; OXIDATION-REDUCTION; PROTEIN AGGREGATION, PATHOLOGICAL; TAU PROTEINS; YOUNG ADULT;

EID: 84919722777     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.219352     Document Type: Article

References (22)

1. Alzheimer A (1907). Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 64:146-148.
2. Arriagada PV, Growdon JH, Hedley-Whyte ET, and Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631-639.
3. Bancher C, Braak H, Fischer P, and Jellinger KA (1993) Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer' s and Parkinson's disease patients. Neurosci Lett 162:179-182.
4. Bancher C, Jellinger K, Lassmann H, Fischer P, and Leblhuber F (1996) Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci 246:137-146.
5. Burhenne J, Riedel KD, Rengelshausen J, Meissner P, Müller O, Mikus G, Haefeli WE, and Walter-Sack I (2008) Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 863:273-282.
6. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, and Kolb HC (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34:457-468.
7. Damian F, Blaton N, Kinget R, and Van den Mooter G (2002) Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire 44/14 and PVP K30. Int J Pharm 244:87-98.
8. Duyckaerts C, Bennecib M, Grignon Y, Uchihara T, He Y, Piette F, and Hauw JJ (1997) Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 18:267-273.
9. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H, and Lipton RB (1999) Memory and mental status correlates of modified Braak staging. Neurobiol Aging 20:573-579.
10. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, et al. (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79: 1094-1108.
11. May JM, Qu ZC, and Cobb CE (2004) Reduction and uptake of methylene blue by human erythrocytes. Am J Physiol Cell Physiol 286:C1390-C1398.
12. May JM, Qu ZC, and Whitesell RR (2003) Generation of oxidant stress in cultured endothelial cells by methylene blue: protective effects of glucose and ascorbic acid. Biochem Pharmacol 66:777-784.
13. Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, et al. (2000) Staging of cytoskeletal and b-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 157:623-636.
14. Murthy ASN and Reddy KS (1984) Cyclic-voltammetric studies of some phenothiazine dyes. J Chem Soc Faraday Trans 1 80:2745-2750.
15. Novak M, Kabat J, and Wischik CM (1993) Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 12:365-370.
16. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, et al. (2014) Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137:1762-1771.
17. Peter C, Hongwan D, Küpfer A, and Lauterburg BH (2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 56:247-250.
18. Taniguchi S, Suzuki N, MasudaM, Hisanaga S, Iwatsubo T, GoedertM, and Hasegawa M (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280:7614-7623.
19. Wilcock GK, Esiri MM, Bowen DM, and Smith CC (1982) Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 57:407-417.
20. Wischik CM, Edwards PC, Lai RY, Roth M, and Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93:11213-11218.
21. Wischik CM, Harrington CR, and Storey JMD (2014) Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 88:529-539.
22. Wischik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, and Klug A (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 85:4506-4510.